Fo­cused on new deals, Bio­gen bags a PhI­II drug for is­chemic stroke with $120M up­front

Bio­gen’s busi­ness de­vel­op­ment team has been on the march.

The big biotech has struck a deal to buy a Phase III drug for is­chemic stroke for $120 mil­lion up front, look­ing to over­see the late-stage pro­gram aimed at ex­pand­ing its port­fo­lio of neu­ro­science drugs.

Bio­gen bought the drug from Rem­e­dy Phar­ma­ceu­ti­cals, which com­plet­ed the mid-stage ef­fort and gath­ered or­phan and fast track sta­tus for Cirara. The drug tack­les SUR1-TRPM4 chan­nels, hit­ting a path­way in­volved in brain swelling, or cere­bral ede­ma. And it will now be put along­side na­tal­izum­ab, a Bio­gen ther­a­py now in Phase IIb for in­flam­ma­tion re­lat­ed to is­chemic stroke.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.